Clinical trials: Refractory Solid Tumors
Solid Tumors
Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of I-131-CLR1404.
- Trial name
- NCT00925275
- Testing
- I-131-CLR1404
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cellectar, Inc
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Tumors
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.
- Trial name
- NCT00339144
- Testing
- Dasatinib
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
Cancer
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
The purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned.
- Trial name
- NCT01495663
- Testing
- I-131-CLR1404
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cellectar Biosciences, Inc.
Solid Tumors
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
EMD Serono has closed enrollment into this trial prior to determination of maximum tolerated dose (MTD). EMD Serono has decided not to pursue the development of EMD 1204831 in patients with advanced solid tumors for reasons other…
- Trial name
- NCT01110083
- Testing
- EMD 1204831
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- EMD Serono
Neoplasms
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.
- Trial name
- NCT00057473
- Testing
- carboplatin + irinotecan, irinotecan
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
Advance Solid Tumors, Lymphoma, Non-Hodgkin
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
- Trial name
- PANGU-1 (NCT07864701)
- Testing
- JMBI-001 Tablets
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chengdu Anticancer Bioscience, Ltd.
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Solid Tumor
A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
Phase Ib is a dose De-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of GT90001 in combination with KN046 in subjects with advanced or refractory hepatocellular…
- Trial name
- NCT04984668
- Testing
- GT90001+KN046, GT90001/KN046
- Where
- Taiwan
- Volunteers
- 216 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Solid Tumor Malignancies
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This protocol will examine the safety of intravenous administration of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C.
- Trial name
- NCT01118819
- Testing
- Clostridium novyi-NT spores
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- BioMed Valley Discoveries, Inc
Advanced Solid Tumor, Anal Cancer
Phase 1 Study of Oral TP-1454
This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.
- Trial name
- NCT04328740
- Testing
- TP-1454 monotherapy
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02587689
- Testing
- anti-MUC1 CAR T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Refractory or Relapsed Solid Tumors, Lymphoma
Phase I/II Study of Avelumab in Pediatric Cancer Participants
This is a multi-center, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in pediatric subjects 0 to less than 18 years of age with…
- Trial name
- NCT03451825
- Testing
- Avelumab
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 21 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumor, Gastric Cancer
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Gastric Cancer, Liver Cancer
- Trial name
- NCT06873659
- Testing
- SON-DP
- Where
- 11 sites in China
- Volunteers
- 96 people
- Sponsor
- Qurgen Inc.
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Her2 Amplified Solid Tumors, Metastatic Breast Cancer
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
This study is an open-label Phase 1 trial of MM-111.
- Trial name
- Monotherapy (NCT00911898)
- Testing
- MM-111
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Merrimack Pharmaceuticals
Neoplasms
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
This Phase 1 study will be conducted in an open-label, non-randomized, dose-escalation design in subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy.
- Trial name
- NCT01585870
- Testing
- Sorafenib (Nexavar, BAY43-9006), Eribulin
- Where
- 4 sites in France, Germany
- Volunteers
- 40 people
- Sponsor
- Bayer